Study probes hidden fear haunting cancer survivors
NCT ID NCT07357311
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how common severe fear of cancer recurrence is among people treated for breast or lung cancer. Researchers will survey 200 patients and interview 40 of them to understand their experiences and what kind of support they need. The goal is to find better ways to spot those who need extra psychological care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors identify patients who need extra psychological support after cancer treatment.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly change or improve patient care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 200 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2025
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with lung cancer or breast cancer at all stages of the disease, three months after treatment completion or three months after the start of a first treatment line for a metastatic progression.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Aged 18 or over * Clinical or pathological diagnosis of primary or recurrence of a localized/loco-regional or metastatic breast cancer, or a stage 1 or 2, or stage 3 or 4 lung cancer; or a breast or lung cancer metastatic progression * Three months after completing treatment or three months after the start of a first treatment line for metastatic progression * Able to comply with the scheduled assessment and interviews * Able to read and understand the questionnaires' language (i.e. French) Exclusion Criteria: * Participating in another patient-reported outcome study interfering with the present study * Any social, medical or psychological condition hindering questionnaire completion * Being deprived of personal liberty or under guardianship
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Institut Curie
RECRUITINGParis, 75005, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a faster radiation course match the standard one after breast reconstruction?
- Surgeons could freeze lung tumors from miles away using 5G robots
- Can High-Risk breast cancer patients skip an extra radiation boost?
- Can AI make lung cancer scans easier to read?
- Radioactive probe lights up CD73 on breast tumors in PET scans
- Two-Drug combo targets Treatment-Resistant lung cancer